Literature DB >> 34125590

In Vitro Antibacterial Activity of Cefiderocol against Multidrug-Resistant Acinetobacter baumannii.

Jacinda C Abdul-Mutakabbir1, Logan Nguyen1, Philip T Maassen1, Kyle C Stamper1, Razieh Kebriaei1, Keith S Kaye2, Mariana Castanheira3, Michael J Rybak1,4,5.   

Abstract

Cefiderocol (CFDC), a novel siderophore cephalosporin, demonstrates strong activity against multidrug-resistant (MDR) Acinetobacter baumannii. Limited studies have evaluated CFDC alone and in combination with other Gram-negative antibiotics against MDR A. baumannii isolates. Susceptibility testing revealed lower CFDC MIC values (87% of MICs ≤ 4mg/liter) than the comparator Gram-negative agents. Six isolates, with elevated CFDC MICs (16 to 32 mg/liter) were selected for further experiments. Time-kill analyses presented with synergistic activity and beta-lactamase inhibitors increased CFDC susceptibility in each of the isolates.

Entities:  

Keywords:  A. baumannii; Gram-negative; cefiderocol; multidrug-resistant infection

Mesh：

Substances：

Year:  2021        PMID： 34125590      PMCID： PMC8370208          DOI： 10.1128/AAC.02646-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  24 in total

1.  Ampicillin/sulbactam (Unasyn).

Authors: 
Journal:  Med Lett Drugs Ther       Date:  1987-08-28       Impact factor: 1.909

2.  Active efflux pump adeB is involved in multidrug resistance of Acinetobacter baumannii induced by antibacterial agents.

Authors:  Tingting Zhang; Min Wang; Yixin Xie; Xianping Li; Zhihui Dong; Yanhua Liu; Ling Wang; Min Yang; Huan Song; Hong Cao; Wei Cao
Journal:  Exp Ther Med       Date:  2017-02-21       Impact factor: 2.447

3.  Structural Basis of Reduced Susceptibility to Ceftazidime-Avibactam and Cefiderocol in Enterobacter cloacae Due to AmpC R2 Loop Deletion.

Authors:  Akito Kawai; Christi L McElheny; Alina Iovleva; Ellen G Kline; Nicolas Sluis-Cremer; Ryan K Shields; Yohei Doi
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

Review 4.  Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.

Authors:  George G Zhanel; Christopher D Lawson; Heather Adam; Frank Schweizer; Sheryl Zelenitsky; Philippe R S Lagacé-Wiens; Andrew Denisuik; Ethan Rubinstein; Alfred S Gin; Daryl J Hoban; Joseph P Lynch; James A Karlowsky
Journal:  Drugs       Date:  2013-02       Impact factor: 9.546

5.  Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: results from CAPITAL Surveillance 2010.

Authors:  Anne Marie Queenan; Chris M Pillar; Jennifer Deane; Daniel F Sahm; A Simon Lynch; Robert K Flamm; Janet Peterson; Todd A Davies
Journal:  Diagn Microbiol Infect Dis       Date:  2012-05-12       Impact factor: 2.803

Review 6.  Anticipating the Unpredictable: A Review of Antimicrobial Stewardship and Acinetobacter Infections.

Authors:  Eric Wenzler; Debra A Goff; Romney Humphries; Ellie J C Goldstein
Journal:  Infect Dis Ther       Date:  2017-03-04

7.  Therapeutic drug monitoring-based dose optimisation of piperacillin/tazobactam to improve outcome in patients with sepsis (TARGET): a prospective, multi-centre, randomised controlled trial.

Authors:  Stefan Hagel; Sandra Fiedler; Andreas Hohn; Alexander Brinkmann; Otto R Frey; Heike Hoyer; Peter Schlattmann; Michael Kiehntopf; Jason A Roberts; Mathias W Pletz
Journal:  Trials       Date:  2019-06-06       Impact factor: 2.279

8.  Meta-analysis of colistin for the treatment of Acinetobacter baumannii infection.

Authors:  Zhijin Chen; Yu Chen; Yaogao Fang; Xiaotian Wang; Yanqing Chen; Qingsong Qi; Fang Huang; Xungang Xiao
Journal:  Sci Rep       Date:  2015-11-24       Impact factor: 4.379

9.  In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016.

Authors:  Meredith A Hackel; Masakatsu Tsuji; Yoshinori Yamano; Roger Echols; James A Karlowsky; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

10.  Carbapenem-Nonsusceptible Gram-Negative Pathogens in ICU and Non-ICU Settings in US Hospitals in 2017: A Multicenter Study.

Authors:  Eilish McCann; Arjun Srinivasan; C Andrew DeRyke; Gang Ye; Daryl D DePestel; John Murray; Vikas Gupta
Journal:  Open Forum Infect Dis       Date:  2018-09-21       Impact factor: 3.835
View more
  8 in total

1.  In vitro and in vivo efficacy of cefiderocol plus tigecycline, colistin, or meropenem against carbapenem-resistant Acinetobacter baumannii.

Authors:  Wentao Ni; Yifan Wang; Xinqian Ma; Yukun He; Jin Zhao; Jie Guan; Yanjun Li; Zhancheng Gao
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2022-10-06       Impact factor: 5.103

Review 2.  Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance.

Authors:  Stamatis Karakonstantis; Maria Rousaki; Evangelos I Kritsotakis
Journal:  Antibiotics (Basel)       Date:  2022-05-27

Review 3.  Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence.

Authors:  Chuanhai Wang; Deqing Yang; Yifan Wang; Wentao Ni
Journal:  Front Pharmacol       Date:  2022-04-12       Impact factor: 5.988

Review 4.  Infectious disease: how to manage Gram-positive and Gram-negative pathogen conundrums with dual beta-lactam therapy.

Authors:  Alireza FakhriRavari; Brenda Simiyu; Taylor Morrisette; Yewande Dayo; Jacinda C Abdul-Mutakabbir
Journal:  Drugs Context       Date:  2022-01-20

5.  In Vitro Activity of KBP-7072 against 536 Acinetobacter baumannii Complex Isolates Collected in China.

Authors:  Renru Han; Li Ding; Yang Yang; Yan Guo; Dandan Yin; Shi Wu; Peiyuan Zhi; Demei Zhu; Qingmei Liu; Xiaojuan Tan; Yuanju Zhu; Jay Zhang; Li Li; Fupin Hu
Journal:  Microbiol Spectr       Date:  2022-02-09

6.  Novel Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Necrotizing Pneumonia Complicated by Empyema: A Case Report.

Authors:  Dana J Holger; Ashlan J Kunz Coyne; Jing J Zhao; Avnish Sandhu; Hossein Salimnia; Michael J Rybak
Journal:  Open Forum Infect Dis       Date:  2022-03-05       Impact factor: 3.835

7.  Pharmacokinetic Analysis and In Vitro Synergy Evaluation of Cefiderocol, Sulbactam, and Tigecycline in an Extensively Drug-Resistant Acinetobacter baumannii Pneumonia Patient Receiving Continuous Venovenous Hemodiafiltration.

Authors:  Emir Kobic; Yasmeen Abouelhassan; Kumara Singaravelu; David P Nicolau
Journal:  Open Forum Infect Dis       Date:  2022-09-21       Impact factor: 4.423

Review 8.  Place in Therapy of the Newly Available Armamentarium for Multi-Drug-Resistant Gram-Negative Pathogens: Proposal of a Prescription Algorithm.

Authors:  Lorenzo Volpicelli; Mario Venditti; Giancarlo Ceccarelli; Alessandra Oliva
Journal:  Antibiotics (Basel)       Date:  2021-11-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.